StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.24−0.09 (-6.77%)

Close on Nov 20, 2026Market cap $12.33MP/E –Yield –

Seres Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Seres Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$51.30M. For fiscal 2025 it was $865.00K. The highest annual figure on record is $22.43M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$865.00K–
FY2024Dec 31, 2024-$148.99M–
FY2023Dec 31, 2023-$125.33M–
FY2022Dec 31, 2022-$238.64M–
FY2021Dec 31, 2021-$2.88M–
FY2020Dec 31, 2020-$94.20M–
FY2019Dec 31, 2019-$77.52M–
FY2018Dec 31, 2018-$64.79M–
FY2017Dec 31, 2017-$80.20M-457.6%
FY2016Dec 31, 2016$22.43M–
FY2015Dec 31, 2015-$45.21M–
FY2014Dec 31, 2014-$11.36M–
FY2013Dec 31, 2013-$5.50M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.39M–
Q1 FY2026Mar 31, 2026-$16.36M-160.9%
Q4 FY2025Dec 31, 2025-$14.74M–
Q3 FY2025Sep 30, 2025$2.20M–
Q2 FY2025Jun 30, 2025-$13.47M–
Q1 FY2025Mar 31, 2025$26.88M–
Q4 FY2024Dec 31, 2024-$38.97M–
Q3 FY2024Sep 30, 2024-$34.81M–
Q2 FY2024Jun 30, 2024-$39.91M-161.6%
Q1 FY2024Mar 31, 2024-$35.30M–
Q4 FY2023Dec 31, 2023-$48.38M–
Q3 FY2023Sep 30, 2023-$61.05M–
Q2 FY2023Jun 30, 2023$64.75M–
Q1 FY2023Mar 31, 2023-$80.65M–
Q4 FY2022Dec 31, 2022-$56.35M–
Q3 FY2022Sep 30, 2022-$60.83M-149.2%
Q2 FY2022Jun 30, 2022-$52.06M–
Q1 FY2022Mar 31, 2022-$69.40M–
Q4 FY2021Dec 31, 2021-$53.44M–
Q3 FY2021Sep 30, 2021$123.65M–
Q2 FY2021Jun 30, 2021-$42.25M–
Q1 FY2021Mar 31, 2021-$30.84M–
Q4 FY2020Dec 31, 2020-$18.15M–
Q3 FY2020Sep 30, 2020-$25.93M–
Q2 FY2020Jun 30, 2020-$25.79M–
Q1 FY2020Mar 31, 2020-$24.32M–
Q4 FY2019Dec 31, 2019-$14.28M-211.0%
Q3 FY2019Sep 30, 2019-$18.42M–
Q2 FY2019Jun 30, 2019-$12.13M–
Q1 FY2019Mar 31, 2019-$32.70M–
Q4 FY2018Dec 31, 2018$12.86M–
Q3 FY2018Sep 30, 2018-$23.56M–
Q2 FY2018Jun 30, 2018-$26.38M–
Q1 FY2018Mar 31, 2018-$27.72M–
Q4 FY2017Dec 31, 2017-$21.29M–
Q3 FY2017Sep 30, 2017-$4.07M–
Q2 FY2017Jun 30, 2017-$26.94M–
Q1 FY2017Mar 31, 2017-$27.90M–
Q4 FY2016Dec 31, 2016-$26.49M–
Q3 FY2016Sep 30, 2016-$17.23M–

More Seres Therapeutics figures

See a number that looks wrong?